DermaGen completes patient enrolment for Phase I/IIa clinical trial

2009-07-06

DermaGen AB has completed patient enrolment for a Phase I/IIa clinical trial for DPK-060, a novel antimicrobial peptide.

The study is composed of two parts; an open safety and local tolerability part and a 1:1 randomized, double-blind efficacy part comparing DPK-060 treatment against a placebo. The study encompasses patients with atopic dermatitis and initial analysis of patient data has already begun.

The primary endpoint of the study is to measure the reduction of microbes in the treated eczemas after DPK-060 therapy compared with placebo treatment. Secondary clinical endpoints in the study include documentation of clinical score of the eczema during and after treatment, safety and local tolerability.

The results from the study are expected to be released in Q3 of 2009.

For more information about DermaGen AB please visit www.dermagen.se

Or contact:

Dr. Jan Alenfall, CEO
Phn: + 46 (0)46 192 197
Mob: + 46 (0)709 315 115
E-mail: jan.alenfall@dermagen.se